Embla Medical hfOSSFF 92 PE Ratio (TTM) is 20.54 as of Jun. 24, 2026, which is 40% below its 10-year median of 34.00. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.49. The stock has 2 warning signs investors should review. Among 437 Medical Devices & Instruments companies, Embla Medical hf ranks better than 62.24% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-06-24), Embla Medical hf's share price is
$4.15.
Embla Medical hf's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.20. Therefore, Embla Medical hf's PE Ratio (TTM) for today is 20.54.
Good Sign:
Embla Medical hf stock PE Ratio (=20.04) is close to 10-year low of 20.04.
The historical rank and industry rank for Embla Medical hf's PE Ratio (TTM) or its related term are showing as below:
OSSFF'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 20.04 Med: 34 Max: 448.61
Current: 20.04
During the past 13 years, the highest PE Ratio (TTM) of Embla Medical hf was 448.61. The lowest was 20.04. And the median was 34.00.
OSSFF's PE Ratio (TTM) is ranked better than 62.24% of 437
companies
in the Medical Devices & Instruments industry
Industry Median: 25.63
vs OSSFF: 20.04
During the past 12 months, Embla Medical hf's average EPS without NRIGrowth Rate was 10.20% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 20.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 48.40% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 2.80% per year.
During the past 13 years, Embla Medical hf's highest 3-Year average EPS without NRI Growth Rate was 238.30% per year. The lowest was -56.80% per year. And the median was 8.50% per year.
Embla Medical hf's EPS (Basic) for the
three
months ended in Mar. 2026 was $0.03.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.20.
Embla Medical hf (OTCPK:OSSFF) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Embla Medical hf PE Ratio (TTM) Related Terms
Embla Medical hf PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Embla Medical hf's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf PE Ratio (TTM) vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Embla Medical hf's Share Price of today is $4.15.
Embla Medical hf's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Embla Medical hf (OSSFF) has a PE Ratio (TTM) of 20.54 as of Jun. 24, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Embla Medical hf and its competitors. This is 40% below median its historical median of 34.00. Over the past decade, Embla Medical hf's PE Ratio (TTM) has ranged from 20.04 to 448.61. According to the industry distribution chart, Embla Medical hf ranks #165 out of 437 companies in the Medical Devices & Instruments industry, placing it in the top 37.8%.
Is Embla Medical hf's PE Ratio (TTM) too high?
Embla Medical hf's current PE Ratio (TTM) of 20.54 is 40% below median its 10-year median of 34.00. Over the past 10 years, this metric has ranged from a low of 20.04 to a high of 448.61. The Medical Devices & Instruments industry median PE Ratio (TTM) is 25.63. Embla Medical hf's value of 20.54 is 19.9% below this industry median. Based on the distribution chart, Embla Medical hf ranks #165 out of 437 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's PE Ratio (TTM) compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #165 out of 437 companies for PE Ratio (TTM). This puts Embla Medical hf in the upper half of its industry. The industry median PE Ratio (TTM) is 25.63. Embla Medical hf's value of 20.54 is 19.9% below this benchmark. Historically, Embla Medical hf's own PE Ratio (TTM) has ranged from 20.04 to 448.61 over the past decade. While the company's 10-year median is 34.00 vs. the industry median of 25.63, Embla Medical hf has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Devices & Instruments company?
The median PE Ratio (TTM) among Medical Devices & Instruments companies is 25.63, based on 437 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current PE Ratio (TTM) of 20.54 is 19.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio (TTM) is 25.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current PE Ratio (TTM) is 20.54, which is 40% below median its own 10-year median of 34.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current PE Ratio (TTM) of 20.54. The stock's GF Value™ is $5.49, compared to a current price of $4.15 — trading 24.4% below its estimated fair value. The current PE Ratio (TTM) is 20.54, which is 40% below median its 10-year median of 34.00 and 19.9% below the Medical Devices & Instruments industry median of 25.63. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current PE Ratio (TTM) is 20.54 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 24.4% below its estimated GF Value™ of $5.49.
Key valuation signals for OSSFF:
PE Ratio (TTM): 20.54 (40% below median its 10-year median of 34.00)
GF Value™: $5.49 vs. price of $4.15 (24.4% below fair value)
Industry Position: 19.9% below the Medical Devices & Instruments median (#165 of 437)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
